Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.57 USD | -3.79% | -1.31% | -28.86% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.86% | 1.55B | |
-19.78% | 10.81B | |
+44.90% | 3.36B | |
-33.46% | 2.22B | |
-14.31% | 2.16B | |
+25.34% | 1.04B | |
-3.28% | 746M | |
-35.33% | 425M | |
-46.53% | 405M | |
+17.30% | 378M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Morgan Stanley Adjusts Price Target on Veracyte to $23 From $22, Maintains Underweight Rating